Endogenous Nonionic Unsaturated Monoethanolamide Lipids as a Posterior Eye Drug Delivery System

内源性非离子不饱和单乙醇酰胺脂质作为眼后药物输送系统

• 批准号: 405754-2011
• 负责人: Lasowski, Frances
• 金额: $ 3.64万
• 依托单位: McMaster University
• 依托单位国家: 加拿大
• 项目类别: Vanier Canada Graduate Scholarships - Doctoral
• 财政年份: 2012
• 资助国家: 加拿大
• 起止时间: 2012-01-01 至 2013-12-31
• 项目状态: 已结题
• 来源: https://www.nserc-crsng.gc.ca/ase-oro/Details-Detailles_eng.asp?id=515601
• 关键词: Endogenous; Nonionic; Unsaturated; Monoethanolamide; Lipids

Retinoblastoma is a cancer of the eye that often affects children by the age of 3. Typical treatments currently include removal of the eye or chemotherapy. While novel therapeutics have been developed that may act as chemo-preventative agents and reduce the incidence of this cancer in susceptible children, the delivery of these drugs to the back of the eye remains an engineering challenge. To accommodate this, both a traditional and a novel drug delivery system are being explored. Due to the nature of the disease, an injection into the eye is undesirable, so sclera delivery methods using both traditional fibrin gels and also lipids which create a gel-like phase are being explored. These materials will be loaded with the required therapeutics and tailored such that the release of the drugs from the materials effectively maintains a therapeutic dose at the retinal site of interest to prevent the cancer formation for the desired length of time. After confirming the release kinetics by in vitro methods, this formulation would then undergo animal testing to confirm the results in vivo and determine any additional benefits or potential side effects. It is also believed that these novel lipids can be injected and will gel in situ, which while not suitable for a retinoblastoma application, will be explored for other posterior eye drug delivery applications such as age-related macular degeneration.

视网膜母细胞瘤是一种眼部癌症，通常影响3岁以下的儿童。目前典型的治疗方法包括摘除眼睛或化疗。虽然已经开发出了新的治疗方法，可以作为化学预防剂并降低易感儿童的癌症发病率，但将这些药物输送到眼后部仍然是一个工程挑战。为了适应这一点，传统的和新的药物输送系统正在探索。由于疾病的性质，注射到眼睛中是不期望的，因此正在探索使用传统纤维蛋白凝胶和产生凝胶样相的脂质的巩膜递送方法。 这些材料将装载所需的治疗剂并进行定制，使得药物从材料中的释放有效地在感兴趣的视网膜部位保持治疗剂量，以防止癌症形成所需的时间长度。在通过体外方法确认释放动力学后，该制剂将进行动物试验以确认体内结果并确定任何额外的益处或潜在的副作用。还认为这些新型脂质可以注射并将原位胶凝，虽然不适合视网膜母细胞瘤应用，但将探索用于其他后眼药物递送应用，如年龄相关性黄斑变性。